Article Link: FDA Approves Qwo (collagenase clostridium histolyticum-aaes) as the First Injectable Treatment for Cellulite DUBLIN, July 6...
FDA Approves Byfavo (remimazolam injection) for the Induction and Maintenance of Procedural Sedation
Article Link: FDA Approves Byfavo (remimazolam injection) for the Induction and Maintenance of Procedural Sedation Dublin, Ireland – 2 Ju...
FDA Approves Rukobia (fostemsavir) for HIV in Adults with Few Treatment Options Available
Article Link: FDA Approves Rukobia (fostemsavir) for HIV in Adults with Few Treatment Options Available July 2, 2020 — ViiV Healthc...
FDA Approves Dojolvi (triheptanoin) for the Treatment of Long-Chain Fatty Acid Oxidation Disorders
Article Link: FDA Approves Dojolvi (triheptanoin) for the Treatment of Long-Chain Fatty Acid Oxidation Disorders NOVATO, Calif., June 30,...
FDA Approves Bavencio as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Article Link: FDA Approves Bavencio as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma &#...
FDA Approves Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) for HER2-Positive Breast Cancer
Article Link: FDA Approves Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) for HER2-Positive Breast Cancer South San Francisco, ...
FDA Approves Merck’s Keytruda (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
Article Link: FDA Approves Merck’s Keytruda (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorec...
FDA Approves Mycapssa (octreotide) Oral Somatostatin Analog for Acromegaly
Article Link: FDA Approves Mycapssa (octreotide) Oral Somatostatin Analog for Acromegaly NEEDHAM, Mass., June 26, 2020 (GLOBE NEWSWIRE) &...
FDA Approves Fintepla (fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome
Article Link: FDA Approves Fintepla (fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome EMERYVILLE, Calif., June...
FDA Approves Merck’s Keytruda (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation
Article Link: FDA Approves Merck’s Keytruda (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcino...
